Tuberculosis and Diabetes Dec. 10, 2009 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 1 of 18

Size: px
Start display at page:

Download "Tuberculosis and Diabetes Dec. 10, 2009 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 1 of 18"

Transcription

1 Screening, Diagnosis, and Treatment of TB in Persons with Diabetes Dean Schillinger, M.D. University of California San Francisco CA Diabetes Program Gisela Schecter, M.D., M.P.H. TB Control Branch CA Department of Public Health Session Overview Discuss the importance of tuberculosis (TB) prevention in people with diabetes mellitus (DM) Translate the understanding that TB and DM frequently coexist into recommendations re TB screening practices among people with DM Provide rationale and recommendations for the treatment of latent TB among people with DM and positive TST or IGRA Session Overview (2) Discuss why persons with DM are at increased risk of active TB Identify the unique aspects of the presentation of active TB disease in patients with diabetes Discuss the response to treatment of active TB disease in persons with diabetes Share some concerns re reciprocal interactions between treatment of TB and blood sugar control Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 1 of 18

2 Case 1 58 yo Latina from Guatemala with DM2 receives primary care in a community clinic Has HbA1c 9.3%, blood pressure 155/88, LDL 131, AST 96, ALT 102 On 8 chronic medications Primary and secondary prevention: Requires annual flu vaccine, retinal exam, foot monofilament exam, microalbuminuria test, blood tests, mammogram, colon/cervical CA screening, dental screening, etc How important is a TST/screening for latent TB? Rationale for LTBI Screening in DM Why treat latent TB in people with diabetes? People with DM have 3-fold greater risk of reactivation of latent TB Attributable risk is significant given growing prevalence of DM globally Derive significant public health benefit (prevention of spread in population) Promote individual well-being (prevention of disease in patient) Novel methods: QuantiFERON testing may make even more feasible IGRAs Interferon Gamma Releasing Assays Whole blood assays for M. tuberculosis infection Recently FDA approved QuantiFERON-TB Gold (2004) QuantiFERON-Gold In-tube (2007) Soon to be only QuantiFERON test available T-Spot TB from Immunotec (UK) (2009) Uses Elispot technology Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 2 of 18

3 Who is at Higher Risk of Latent TB Infection? [and deserves to be screened] Foreign-born Homeless/marginally housed Injection drug use Racial/ethnic minority populations Recent contact to TB case Who is at Particular Risk of TB Reactivation? Recent contact to TB case Diabetes Other medical conditions: Renal failure/dialysis Tobacco use S/p Gastrectomy/jejuno-ileal bypass Transplant HIV Other immunosuppressed states, esp. anti-tnf alpha agents, steroids Case 1(a) Patient is screened and found to have a 11 mm. Chest x-ray (CXR) is WNL Should she be treated? If so, for how long, and what concerns might arise re her co-existing diabetes? Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 3 of 18

4 Treatment of Latent TB with NL CXR in Immigrant Patient with DM2 Length of treatment: Isoniazid (INH) x 9 months (>90% success) Or Rifampin (RIF) for 4 mos if INH not tolerated or contact to INH-resistant case Importance of vitamin i B6 ( mg) for neuropathy prevention What about abnormal LFTS? Non-alcoholic hepatic steatosis (NASH) very common in DM Many DM meds cause LFT elevations Not a contraindication to INH prophylaxis Monitor monthly LFTs. Stop INH if 3x increase from baseline Case 1(b) Patient is screened and found to have 11mm CXR is abnormal ( old fibrotic changes ) Audience Response Question #1 Should anything be done differently from Case 1(a)? Yes No Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 4 of 18

5 Rule out Active TB Disease before Initiating Treatment for Latent TB Obtain sputum samples x 3 for patients with abnormal CXRs, even if asymptomatic Await sputum cultures prior to LTBI treatment Then INH x 9 mos, or INH/Rifampin x 4 mos because fibrotic changes Case 2 66 y.o.. Native American male with history of diabetes mellitus (on Glipizide and Rosiglitazone) and peripheral neuropathy; HbA1c 8.9% Presented to emergency department (ED) with complaints of cough for 2-3 weeks, some weight loss and fatigue CXR: RLL infiltrate Given Levofloxacin for 10 days and sent home to follow up with primary care physician (PCP) Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 5 of 18

6 Case 2 (2) Felt somewhat better and did not follow up 2 months later, returned to ED now c/o 20 pound weight loss, now with hemoptysis, fever, and night sweats Chest radiograph now showed extensive RLL infiltrate and extension of disease into L perihilar region Despite technical advances, clinical acumen with a high index of suspicion remains vital to the diagnosis of TB. Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 6 of 18

7 Case 2 (3) The patient was admitted and placed in isolation Weight = 166 lbs TST = 0 mm Sputum smear 3+ AFB NAAT test not available in this rural area Audience Response Question #2 Is this likely to be TB? Yes No Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 7 of 18

8 Case 2 (4) Cr, electrolytes, glucose, and LFTs were obtained Cr = 1.0, plasma glucose = 206, LFTs and electrolytes normal Case 2 (5) The patient was begun on: INH 300 mg daily Rifampin 600 mg daily Pyrazinamide 1,750 mg daily Ethambutol 1,200 mg daily Vitamin B6 50 mg daily Case 2 (6) Lives alone in a trailer Difficult patient Several times refused directly observed therapy (DOT) for a variety of reasons Blood sugar control worsened after beginning TB treatment, with random blood sugars in the 300 and 400 s Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 8 of 18

9 Audience Response Question #3 Why is glucose control worsening? The patient has drug-resistant resistant disease and his TB is worsening He is not taking his diabetes medications His TB treatment negatively affects his glycemic control He is feeling much better and eating more Case 2 (7) Glipizide and Rosiglitazone were both already at maximum dosage, so Metformin at 500 mg 3 x daily was begun, with improvement in glucose control Case 2 (8) Drug susceptibility test (DST) shows pan- susceptible TB Sputum smears positive at 4 weeks but converted to negative after 8 weeks of treatment Sputum cultures still positive after 8 weeks, negative at 12 weeks Patient coughing less, regaining weight Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 9 of 18

10 Audience Response Question #4 What is your recommendation for the continuation phase of treatment? INH and RIF for additional 4 months INH and RIF for additional 7 months Treatment of TB Standard Regimen for INH-Susceptible TB Initial Phase Continuation Phase Extended Continuation Phase Isoniazid Rifampin Pyrazinamide Ethambutol 5 mg/kg up to 300 mg 10 mg/kg up to 600 mg mg/kg mg/kg 0 1 2* Months *ATS/CDC/IDSA Treatment Guidelines: If culture + after 2 months rx and cavitary CXR, prolong continuation phase to 7 months, for a total duration of 9 months. Treatment of TB Increased Risk of Relapse 2-month culture status and presence of cavitation correlates with the likelihood of relapse: Continuation INH/RIF biw Cavity Culture 2 mos Yes No Yes 20.8% 4.7% No 5.9% 1.7% TBTC. Lancet 2002; 360:528 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 10 of 18

11 Case 2 (9) Over the last 7 months of treatment the patient missed 23 DOT doses. You are planning a 9-month regimen When should he finish treatment? Case 2 (10) The patient completed 9 months plus 23 doses and did very well He established a good relationship with his care providers and has made good lifestyle changes so that his diabetes is in much better control LTBI and Progression to Active TB Disease Greater in DM Systematic Review, observational studies that reported an ageadjusted estimate of association between TB and DM Almost 1.8 million participants 3 cohort studies gave RR of 3.11 (CI ) 10 case/control studies odds ratios ranged from Effect was higher in non-north American studies Jeon CY, PLos Med Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 11 of 18

12 LTBI and Progression to Active TB Disease Greater in DM (2) Contacts with Diabetes A Hong Kong study examined 4,661 close contacts to TB cases Both early (within 3 months) and late (followed for 5 years) disease in contacts was strongly associated with diabetes in the contact (RR = 3.44) Lee MS, Int J Tuberc Lung Dis Attributable Risk is a Function of Relative Risk and Underlying Prevalence RR if factor present Prevalence of factor HIV 8.3 1% 7% D.M % 6% Population attributable risk % 17% % 29% Raviglione, WHO Population Attributable Risk Epidemiologic model from India, calculated that diabetes accounted for 14.8% of pulmonary tuberculosis, and 20.2% of smear + tuberculosis Stevenson CR, BMC Public Health, 2007 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 12 of 18

13 LTBI and Progression to Active TB Disease Why are patients with diabetes at increased risk for progressing to active TB disease? Impaired cell-mediated immunity Renal failure Micronutrient deficiency Pulmonary microangiopathy Harries AD, Trans Royal S of Trop Med & Hyg Unique Patterns regarding TB Presentation and Diagnosis in DM Diabetes and radiological presentation of pulmonary TB Cavitary lung lesions Yes DM = 50.8% No DM = 39% Lower lobe lung lesions Yes DM; 23.5% lower lobe lesions only No DM; 2.4% lower lobe lesions only Shaikh MA, Saudi Med J, 2003 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 13 of 18

14 Presentation and Diagnosis of TB in Patients with Diabetes More advanced disease Patients with diabetes are more frequently smear + Cavitary findings Hemoptysis more common Fever more common Unclear if this a result of delay in diagnosis or more rapid disease progression? Wang CS, Epidemiol Infect, 2008 California Experience 280 patients with active pulmonary TB disease Self-reported DM = 20% Sputum smear + Yes DM = 66% No DM = 45% Cavitary CXR findings Yes DM = 31% No DM = 14% Suboptimal Response to TB Treatment in DM Old dogma: despite increased risk of progression to active TB disease, these patients did just as well 4 new studies Baltimore: delayed culture conversion, higher mortality Texas: delayed sputum culture conversion Taiwan: higher mortality Indonesia: slower smear and culture conversion Dooley, Tang, Am J Trop Med Hyg ; Restrepo, Fisher-Hoch, Am J Trop Med Hyg. 2008; Wang, Yang, Chen, Epidemiol Infect. 2008; Alisjahbana, Sahiratmadja, Clin Infect Dis Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 14 of 18

15 California Experience (2) Patients with active pulmonary TB disease Culture conversion within 90 days Yes DM = 85.7% No DM = 92.0% Response to Treatment Data on drug resistance is less clear, with some studies showing increased drug resistance in patients with diabetes, but others not Relapse may be more frequent, recently shown again in a Shanghai study Patients with DM, 20% relapse with 6 month rx Patients w/o DM, 5.3% relapse with 6 month rx Zhang Q, et.al. Jpn. J Infect Dis, 2009 Rifampin Concentrations May be Lower in DM Comparison of 17 age and sex matched persons with and 17 without DM (all had TB) AUC TB and DM AUC TB only Peak levels also about half in persons with DM Low levels associated with higher body weight and poor glucose control Consider rifampin levels for slow conversion of sputum Nijland HM, Clin Infect Dis, 2006 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 15 of 18

16 TB and DM Treatment Caveats Pyrazinamide (PZA) and Ethambutol (EMB) need adjustment for renal impairment; check serum Cr INH-related peripheral neuropathy is more common in diabetes: should give Vitamin B6 Follow closely and monitor for sputum conversion Extend treatment to 9 months if slow sputum conversion OR cavitary CXR, consider rifampin levels TB and DM Treatment Caveats (2) Rifampin raises blood glucose levels even in non-diabetic Rifampin activates the CYP450 enzyme system Sulfonylureas and thiazolidinediones are metabolized by this same system Blood levels of these drugs significantly lowered by rifampin As a result, blood glucose control in people with diabetes may worsen when treating TB Monitoring for Hepatotoxicity Many patients with diabetes are on statins, as well as the thiazolidinediones, which carry risk of hepatotoxicity Now we add 3 anti-tb drugs with potential for liver toxicity: INH, PZA, and RIF These patients should have careful, monthly LFT follow-up, and if 5 x normal values, treatment should be adjusted Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 16 of 18

17 Treatment Success Requires Communication Typically, the TB provider (often the health department) will not also treat the diabetes and vice versa Because of the effect of TB treatment on glycemic control, critical importance of 2-way communication between TB and DM providers, at onset, during, and at end of treatment Treatment Success Requires Communication (2) Equally important is patient/provider communication Communication barriers are very common among low-income, diverse patients with DM Limited literacy/numeracy (>50%) Limited English proficiency Sensory deficits are common: vision and hearing loss Subtle cognitive impairment common among those with longstanding DM Use the teach-back method Schillinger. JAMA 2002 Recommendations Just as we recommend screening TB patients for HIV, screen for DM when TB is diagnosed (FBS >125=DM) Repeat serum glucose after one month Monitor for polyuria/polydipsia during treatment If diabetes is present, treat, don t wait Follow diabetes closely and bring blood sugar as close to normal as possible Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 17 of 18

18 Conclusions DM increases risk of LTBI progressing to disease Patients with diabetes and risk factors need LTBI screening and rx Active TB disease may present differently in people with diabetes Patients with diabetes may clear sputum more slowly and have higher mortality Consider prolonging treatment if risk factors for relapse are present Monitor diabetes control closely at onset and at end of rx; attempt to achieve optimal glycemic control, including use of insulin if necessary Always use vitamin B6 if on INH Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 18 of 18

Diagnosis and Treatment of Tuberculosis, 2011

Diagnosis and Treatment of Tuberculosis, 2011 Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is

More information

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012 TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release

More information

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection

More information

TB Intensive San Antonio, Texas May 7-10, 2013

TB Intensive San Antonio, Texas May 7-10, 2013 TB Intensive San Antonio, Texas May 7-10, 2013 TB and Diabetes Barbara Seaworth, MD May 09, 2013 Barbara Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial

More information

Northwestern Polytechnic University

Northwestern Polytechnic University Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions

More information

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has

More information

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division

More information

Treatment of Tuberculosis, 2017

Treatment of Tuberculosis, 2017 Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,

More information

Tuberculosis Tools: A Clinical Update

Tuberculosis Tools: A Clinical Update Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary

More information

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures

More information

A look at medical factors that increase the risk for TB disease

A look at medical factors that increase the risk for TB disease A look at medical factors that increase the risk for TB disease Mark Lobato, MD New England TB Consultant Division of Tuberculosis Elimination CDC Overview The spectrum of M. tuberculosis infection Immune

More information

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

TB Nurse Case Management San Antonio, Texas July 18 20, 2012 TB Nurse Case Management San Antonio, Texas July 18 20, 2012 TB and Diabetes Barbara Seaworth, MD July 19, 2012 Barbara Seaworth, MD, FIDSA, FACP has the following disclosures to make: Has an advisory

More information

Fundamentals of Tuberculosis (TB)

Fundamentals of Tuberculosis (TB) TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported

More information

Substance Abuse and Tuberculosis Springfield, IL April 27, 2011

Substance Abuse and Tuberculosis Springfield, IL April 27, 2011 Substance Abuse and Tuberculosis Springfield, IL April 27, 2011 Co-morbidities in Substance Abuse that Impact Managing TB Lisa Armitige, MD, PhD April 27, 2011 Lisa Armitige, MD, PhD has the following

More information

Errors in Dx and Rx of TB

Errors in Dx and Rx of TB Errors in Dx and Rx of TB David Schlossberg, MD, FACP Professor of Medicine Temple University School of Medicine Medical Director, TB Control Program Philadelphia Department of Public Health TB Still a

More information

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case

More information

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014 What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks

More information

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed

More information

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015 Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE

More information

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015 Diagnosis and Medical Management of TB Disease Quratulian Annie Kizilbash, MD, MPH March 17, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION Quratulian

More information

TB in Corrections Phoenix, Arizona

TB in Corrections Phoenix, Arizona TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests

More information

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

TUBERCULOSIS. Presented By: Public Health Madison & Dane County TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any

More information

Tuberculosis: A Provider s Guide to

Tuberculosis: A Provider s Guide to Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency

More information

TB in the Patient with HIV

TB in the Patient with HIV TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to

More information

Screening and Treatment Recommendations for Persons Exposed to MDR TB

Screening and Treatment Recommendations for Persons Exposed to MDR TB Screening and Treatment Recommendations for Persons Exposed to MDR TB Although all persons at increased risk of tuberculosis (TB) infection should be screened for TB infection per USPTF/CDC guidelines

More information

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening

More information

Latent Tuberculosis Best Practices

Latent Tuberculosis Best Practices Latent Tuberculosis Best Practices Last Updated September 7, 2016 LTBI Demographics in the US o 13million people in the US with LTBI (estimate) o In 2014, approximately 66% of TB cases in the United States

More information

TB Intensive San Antonio, Texas December 1-3, 2010

TB Intensive San Antonio, Texas December 1-3, 2010 TB Intensive San Antonio, Texas December 1-3, 2010 TB & Diabetes Barbara Seaworth, MD; HNTC December 3, 2010 Dual Epidemic Diabetes - Tuberculosis Barbara J. Seaworth MD Medical Director, Heartland NTBC

More information

Diagnosis and Medical Management of Latent TB Infection

Diagnosis and Medical Management of Latent TB Infection Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,

More information

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI: Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global

More information

Treatment of Tuberculosis

Treatment of Tuberculosis TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features

More information

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population

More information

TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012

TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012 TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012 Challenges of TB Treatment in Special Populations in Corrections Marcos Burgos, MD November 28, 2012 Marcos Burgos, MD has the following

More information

Drug Interactions Lisa Armitige, MD, PhD November 17, 2010

Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant

More information

has the following disclosures to make:

has the following disclosures to make: CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash

More information

TB Intensive San Antonio, Texas May 7-10, 2013

TB Intensive San Antonio, Texas May 7-10, 2013 TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant

More information

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN

More information

Tuberculosis Intensive November 17 20, 2015 San Antonio, TX

Tuberculosis Intensive November 17 20, 2015 San Antonio, TX Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures

More information

INDEX CASE INFORMATION

INDEX CASE INFORMATION Instructions for Completing the MDH Tuberculosis Contact Investigation Report Form Please provide as much information as possible. Each field represents information that is important to the contact investigation.

More information

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

TB Nurse Case Management San Antonio, Texas July 18 20, 2012 TB Nurse Case Management San Antonio, Texas July 18 20, 2012 Pediatric TB Kim Smith, MD, MPH July 19, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant

More information

TB and Comorbidities Adriana Vasquez, MD April 12, 2018

TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Adriana Vasquez, MD has the following disclosures to make:

More information

Tuberculosis Populations at Risk

Tuberculosis Populations at Risk Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading

More information

Contact Investigation

Contact Investigation Tuberculosis Ann Raftery, RN, PHN, MSc GHS Learning Objectives Upon completion of this session, participants will be able to: Describe the criteria used and method for determining the infectious period

More information

TB Classification (ATS/CDC)

TB Classification (ATS/CDC) bits and pieces Lisa Chen, MD UCSF Pulmonary/Critical Care Curry International Tuberculosis Center 10/2017 TB Classification (ATS/CDC) TB0 No tuberculosis exposure, not infected TB1 Tuberculosis exposure,

More information

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000

More information

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict

More information

TB Intensive San Antonio, Texas November 11 14, 2014

TB Intensive San Antonio, Texas November 11 14, 2014 TB Intensive San Antonio, Texas November 11 14, 2014 TB and Diabetes Barbara Seaworth, MD November 13, 2014 Barbara Seaworth, MD has the following disclosures to make: No conflict of interests No relevant

More information

My heart is racing. Managing Complex Cases. Case 1. Case 1

My heart is racing. Managing Complex Cases. Case 1. Case 1 Managing Complex Cases My heart is racing Amee Patrawalla, MD April 7, 2017 Case 1 Rutgers, The State University of New Jersey Rutgers, The State University of New Jersey Case 1 29 year old physician from

More information

Contact Investigation and Prevention in the USA

Contact Investigation and Prevention in the USA Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis

More information

Managing the Patients Response to TB Treatment

Managing the Patients Response to TB Treatment Managing the Patients Response to TB Treatment Barbarah Martinez, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Barbarah Martinez, RN, BSN has

More information

TUBERCULOSIS. Pathogenesis and Transmission

TUBERCULOSIS. Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are

More information

Diabetes and Tuberculosis: A Practical Approach to Diagnosis and Treatment

Diabetes and Tuberculosis: A Practical Approach to Diagnosis and Treatment Diabetes and Tuberculosis: A Practical Approach to Diagnosis and Treatment Michael Lauzardo, MD MSc Chief, Division of Infectious Diseases and Global Medicine Director, Southeastern National Tuberculosis

More information

Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer

Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Tuberculosis in the 21 st Century Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Feedback Poll In my opinion, the recent media coverage of

More information

Latent TB Infection (LTBI)

Latent TB Infection (LTBI) Latent TB Infection (LTBI) Diagnosis & Treatment of Latent TB Infection (LTBI) Amee Patrawalla MD MPH Assistant Professor UMDNJ-New Jersey Medical School Infection with Mycobacterium tuberculosis without

More information

Disclosures. TB and CoMorbidities Challenges and Opportunities. Burden of TB. Outline of the lecture. Target testing for TB Infection TB HIV 3/25/2012

Disclosures. TB and CoMorbidities Challenges and Opportunities. Burden of TB. Outline of the lecture. Target testing for TB Infection TB HIV 3/25/2012 Disclosures TB and CoMorbidities Challenges and Opportunities E. Jane Carter, M.D. Associate Professor of Medicine Alpert School of Medicine, Brown University Providence, Rhode Island No financial disclosures

More information

CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease

CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease Barbara J Seaworth MD Medical Director Heartland National TB Center Professor of Medicine University of Texas Health Center Tyler Barbara J Seaworth MD has

More information

Latent TB, TB and the Role of the Health Department

Latent TB, TB and the Role of the Health Department Latent TB, TB and the Role of the Health Department Elaine Darnall, RN, BSN, CIC TB Nurse Consultant Illinois Dept of Public Health March 21, 2018 Elaine Darnall has disclosed that there is no actual or

More information

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009 TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages

More information

Treating TB What Happened? All the Patients Have Challenging Co-Morbid Conditions Now!

Treating TB What Happened? All the Patients Have Challenging Co-Morbid Conditions Now! EXCELLENCE EXPERTISE INNOVATION Treating TB What Happened? All the Patients Have Challenging Co-Morbid Conditions Now! Barbara J Seaworth, MD, Medical Director, Heartland National TB Center Professor,

More information

Anti Tuberculosis Medications: Side Effects & adverse Events

Anti Tuberculosis Medications: Side Effects & adverse Events Anti Tuberculosis Medications: Side Effects & adverse Events Diana Fortune, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Diana Fortune, RN,

More information

Tuberculosis Intensive

Tuberculosis Intensive Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 TB in the HIV Patient Lisa Armitige, MD, PhD April 6, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests

More information

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013 Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013 1 TB in Toronto - risk groups Diagnosis of active TB LTBI diagnosis and management Infection control 2 TB in Toronto Case

More information

Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)

Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) CURTIS FOWLER MPT,PA C ASSISTANT CLINICAL PROFESSOR UNIVERSITY OF THE PACIFIC Learning objectives Recognize the appropriate

More information

LATENT TUBERCULOSIS SCREENING AND TREATMENT:

LATENT TUBERCULOSIS SCREENING AND TREATMENT: LATENT TUBERCULOSIS SCREENING AND TREATMENT: TB or not TB Christopher Kwong, MD and William Rifkin, MD Week 14 Educational Objectives: 1. Understand who should be screened for latent TB infection and why

More information

TB Nurse Case Management San Antonio, Texas April 9-11, 2013

TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,

More information

TB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make:

TB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make: TB Intensive San Antonio, Texas August 2-5, 2011 TB/HIV Co-Infection Lisa Armitige, MD, PhD August 4, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant

More information

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016 Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the

More information

Case Management of the TB/HIV Infected Patient

Case Management of the TB/HIV Infected Patient TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected

More information

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active

More information

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict

More information

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017 Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has

More information

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening

More information

LATENT TUBERCULOSIS. Robert F. Tyree, MD

LATENT TUBERCULOSIS. Robert F. Tyree, MD LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION

More information

Standard TB Treatment

Standard TB Treatment Standard TB Treatment Chris Keh, MD TB Controller, TB Prevention and Control Program, San Francisco Department of Public Health Assistant Clinical Professor, Division of Infectious Diseases, University

More information

6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None

6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None TB TREATMENT Bijan Ghassemieh, MD Seattle TB Clinical Intensive 2018 Disclosures None 1 Objectives Understand the following Rationale and goals for standard TB regimen When to initiate TB treatment Standard

More information

The Public Health Impact of TB in the Correctional System. Sarah Bur, RN, MPH Federal Bureau of Prisons Infection Prevention and Control Officer

The Public Health Impact of TB in the Correctional System. Sarah Bur, RN, MPH Federal Bureau of Prisons Infection Prevention and Control Officer The Public Health Impact of TB in the Correctional System Sarah Bur, RN, MPH Federal Bureau of Prisons Infection Prevention and Control Officer The Public Health Impact of TB in the Correctional System

More information

Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program

Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program Topics of Discussion TB Overview Epidemiology of TB in Oregon Annual Facility

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL PAGE 1 of 7 References Related ACA Standards 4 th Edition Standards for Adult Correctional Institutions 4-4350, 4-4355 These guidelines are based on the recommendations of the American Thoracic Society

More information

TB Nurse Case Management San Antonio, Texas March 7 9, Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012

TB Nurse Case Management San Antonio, Texas March 7 9, Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012 TB Nurse Case Management San Antonio, Texas March 7 9, 2012 Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012 Kim Connelly Smith, MD, MPH has the following disclosures to make: No conflict of interests

More information

Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016

Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016 Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016 TB Nurse Case Management September 7-9, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Jessica Quintero, M.Ed., has the following disclosures

More information

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis?

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis? Tuberculosis Understanding, Investigating, Eliminating Jeff Maupin, RN Tuberculosis Control Nurse Sedgwick County Division of Health Objectives At the conclusion of this presentation, you will be able

More information

Tuberculosis Intensive

Tuberculosis Intensive Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Childhood Tuberculosis Kim Smith, MD, MPH April 6, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant

More information

Tuberculosis: update 2013

Tuberculosis: update 2013 Tuberculosis: update 2013 William R. Bishai, MD, PhD Center for TB Research Division of Infectious Diseases Department of Medicine Johns Hopkins School of Medicine Question 1 A TB speaker at a major conference

More information

Pediatric TB Intensive Houston, Texas October 14, 2013

Pediatric TB Intensive Houston, Texas October 14, 2013 Pediatric TB Intensive Houston, Texas October 14, 2013 Diagnosis and Management of Tuberculosis in Adolescents Andrea T. Cruz, MD, MPH Sections of Infectious Diseases & Emergency Medicine October 14, 2013

More information

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either

More information

TB Update: March 2012

TB Update: March 2012 TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their

More information

TUBERCULOSIS CONTACT INVESTIGATION

TUBERCULOSIS CONTACT INVESTIGATION TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE TUBERCULOSIS CONTACT INVESTIGATION LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. Describe the criteria used

More information

TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION

TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION Michelle Haas, M.D. Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES No relevant financial relationships OBJECTIVES

More information

TB Intensive San Antonio, Texas

TB Intensive San Antonio, Texas TB Intensive San Antonio, Texas April 6-8, 2011 TB Disease: ATS/CDC/IDSA Guidelines Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received

More information

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Tuberculosis Pathogenesis and Treatment of Latent TB Infection Lisa Armitige, MD, PhD August 13, 2014 Lisa Armitige,

More information

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection? Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:

More information

ATS/CDC Guidelines for Treating Latent TB Infection

ATS/CDC Guidelines for Treating Latent TB Infection TB Intensive Tyler, Texas June 2-4, 2010 ATS/CDC Guidelines for Treating Latent TB Infection Timothy R. Aksamit, MD June 2, 2010 ATS/CDC Guidelines for Treating LTBI Tuberculosis Intensive University of

More information

Debbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas

Debbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Debbie Onofre, RN, BSN March 18, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with

More information

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female % San Joaquin County (SJC) in 03, (N=43) County Rate = 6. Cases per 00,000 Population I. Demographic Information Table I-A: TB cases by gender, SJC, 03 (N=43) GENDER NUMBER OF CASES Male 6 60.5% Female 7

More information

Treatment of Tuberculosis

Treatment of Tuberculosis TB Intensive Tyler, Texas June 1-3, 2009 Treatment of Tuberculosis Barbara Seaworth, MD June 3, 2009 Treatment of Tuberculosis Barbara J Seaworth MD Medical Director Heartland National TB Center 1 Purpose

More information

TB and Diabetes Intersection of Two Diseases

TB and Diabetes Intersection of Two Diseases TB and Diabetes Intersection of Two Diseases E. Jane Carter, M.D. Associate Professor of Medicine Alpert School of Medicine at Brown University Providence, Rhode Island Disclosures No financial disclosures

More information